185 related articles for article (PubMed ID: 10160480)
1. Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
Zarkin GA; Bala MV; Wood LL; Bennett CL; Simpson K; Dohn MN
Pharmacoeconomics; 1996 Jun; 9(6):525-34. PubMed ID: 10160480
[TBL] [Abstract][Full Text] [Related]
2. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
3. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ
Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
6. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
Spencer CM; Goa KL
Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
[TBL] [Abstract][Full Text] [Related]
7. Atovaquone: a new antipneumocystis agent.
Artymowicz RJ; James VE
Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
[TBL] [Abstract][Full Text] [Related]
8. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P
J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Deresinski SC
Semin Respir Infect; 1997 Jun; 12(2):79-97. PubMed ID: 9195673
[TBL] [Abstract][Full Text] [Related]
10. Atovaquone: a review.
Haile LG; Flaherty JF
Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
[TBL] [Abstract][Full Text] [Related]
11. Optimizing PCP therapy.
Torres G; Cadman J
GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
[TBL] [Abstract][Full Text] [Related]
12. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Korraa H; Saadeh C
South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
[TBL] [Abstract][Full Text] [Related]
13. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Castro M
Semin Respir Infect; 1998 Dec; 13(4):296-303. PubMed ID: 9872626
[TBL] [Abstract][Full Text] [Related]
15. FDA approves new PCP drug. Food and Drug Administration.
AIDS Alert; 1995 Aug; 10(8):108. PubMed ID: 11362680
[TBL] [Abstract][Full Text] [Related]
16. [Therapy and prevention of pneumocystis carinii pneumonia].
Goebel FD; Bogner JR
Internist (Berl); 1995 Dec; 36(12):1150-5. PubMed ID: 8567220
[No Abstract] [Full Text] [Related]
17. Pneumocystis carinii pneumonia treatment in people infected with HIV.
Bellamy R
Clin Evid; 2004 Jun; (11):935-50. PubMed ID: 15652046
[No Abstract] [Full Text] [Related]
18. Pharmacoeconomics of Pneumocystis carinii pneumonia in HIV-infected and HIV-noninfected patients.
Nicolau DP; Ross JW; Quintiliani R; Nightingale CH
Pharmacoeconomics; 1996 Jul; 10(1):72-8. PubMed ID: 10160471
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia.
White A; LaFon S; Rogers M; Andrews E; Brown N
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):280-5. PubMed ID: 7788426
[TBL] [Abstract][Full Text] [Related]
20. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
